75.75

3.09% 2.27

After Hours: 75.76 0.01 +0.01%

Boston Scientific Corp (BSX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Boston Scientific Corp stock is traded at $75.75, with a volume of 13.00M. It is up +3.09% in the last 24 hours and down -19.03% over the past month. Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Previous Close:

$73.48

Open:

$74

24h Volume:

13.00M

Relative Volume:

0.97

Market Cap:

$112.40B

Revenue:

$20.08B

Net Income/Loss:

$2.89B

P/E Ratio:

39.06

EPS:

1.9391

Net Cash Flow:

$3.66B

1W Performance:

+0.04%

1M Performance:

-19.03%

6M Performance:

-28.80%

1Y Performance:

-25.41%

1-Day Range:

$73.66

$75.87

1-Week Range:

$73.44

$75.87

52-Week Range:

$72.69

$109.50

Boston Scientific Corp Stock (BSX) Company Profile

Name

Boston Scientific Corp

Sector

Healthcare (1110)

Industry

Medical Devices (139)

Phone

508-683-4000

Address

300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA

Employee

59,000

Twitter

@bostonsci

Next Earnings Date

2025-10-22

Latest SEC Filings

BSX's Discussions on Twitter

Compare BSX vs ABT, SYK, MDT, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BSX Boston Scientific Corp	75.75	109.04B	20.08B	2.89B	3.66B	1.9391
ABT Abbott Laboratories	116.26	199.55B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	386.06	146.96B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	97.03	123.91B	35.48B	4.64B	5.41B	3.582
EW Edwards Lifesciences Corp	85.90	48.40B	6.07B	1.06B	799.60M	1.8527

Boston Scientific Corp Stock (BSX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-03-25	Downgrade	Erste Group	Buy → Hold
Sep-08-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-16-25	Initiated	Leerink Partners	Outperform
Apr-16-25	Upgrade	Needham	Hold → Buy
Jan-10-25	Upgrade	Deutsche Bank	Hold → Buy
Oct-18-24	Downgrade	Needham	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Feb-01-24	Upgrade	Mizuho	Neutral → Buy
Jul-19-23	Initiated	Robert W. Baird	Outperform
Jun-30-23	Initiated	CL King	Buy
May-30-23	Resumed	Morgan Stanley	Overweight
Mar-29-23	Initiated	UBS	Buy
Dec-22-22	Initiated	Mizuho	Neutral
Dec-20-22	Resumed	Citigroup	Buy
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Buy
Jul-06-22	Initiated	Wolfe Research	Outperform
May-27-22	Upgrade	Needham	Hold → Buy
Apr-13-22	Resumed	Truist	Buy
Mar-02-22	Resumed	BofA Securities	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
May-26-21	Downgrade	Needham	Buy → Hold
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Overweight
Sep-17-20	Initiated	Truist	Buy
Sep-11-20	Initiated	Wolfe Research	Peer Perform
Apr-22-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-01-20	Upgrade	Goldman	Neutral → Buy
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Buy
Dec-30-19	Reiterated	Cowen	Outperform
Dec-19-19	Downgrade	Needham	Strong Buy → Buy
Sep-05-19	Resumed	JP Morgan	Overweight
Sep-03-19	Resumed	Barclays	Overweight
May-13-19	Upgrade	Evercore ISI	In-line → Outperform
Nov-28-18	Initiated	UBS	Buy
Oct-16-18	Initiated	Barclays	Overweight
Oct-02-18	Reiterated	Morgan Stanley	Overweight
Sep-07-18	Reiterated	Needham	Strong Buy
Sep-04-18	Upgrade	Jefferies	Hold → Buy
Jul-06-18	Reiterated	Needham	Strong Buy
Jun-27-18	Initiated	Bernstein	Outperform
Apr-26-18	Reiterated	Needham	Strong Buy

View All

Boston Scientific Corp Stock (BSX) Latest News

03:36 AM

Is Boston Scientific Stock Underperforming the Dow? - Barchart.com

03:36 AM

Feb 25, 2026

Q4 Earnings Highlights: Boston Scientific (NYSE:BSX) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Finviz

Feb 25, 2026

Feb 24, 2026

Boston Scientific Adds Starbucks And Takeda Leaders To Guide Capital And Growth - Yahoo Finance

Feb 24, 2026

Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree - The Business Journals

Feb 24, 2026

Boston Scientific adds Starbucks CFO and biopharma giant CEO to board - Worcester Business Journal

Feb 24, 2026

Feb 23, 2026

Boston Scientific (BSX) Expands Board and Increases Stock Repurc - GuruFocus

Feb 23, 2026

Boston Scientific (BSX) Increases Stock Buyback Program by $4 Bi - GuruFocus

Feb 23, 2026

Boston Scientific (BSX) expands board, approves $5.0B share repurchase plan - Stock Titan

Feb 23, 2026

Here is Why Boston Scientific Corporation (BSX) is Highly Favored by Hedge Funds - Insider Monkey

Feb 23, 2026

Global Neuromodulation Devices Market Anticipating Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight - GlobeNewswire Inc.

Feb 23, 2026

Former Boston Scientific Executive Joins Ceryx Medical’s Board - Medical Product Outsourcing

Feb 23, 2026

Penumbra earnings on deck as Boston Scientific deal looms By Investing.com - Investing.com South Africa

Feb 23, 2026

Penumbra earnings on deck as Boston Scientific deal looms - Investing.com

Feb 23, 2026

Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors - Finviz

Feb 23, 2026

Tredje AP fonden Has $104.53 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat

Feb 21, 2026

King Luther Capital Management Corp Grows Stake in Boston Scientific Corporation $BSX - MarketBeat

Feb 21, 2026

Fiera Capital Corp Takes Position in Boston Scientific Corporation $BSX - MarketBeat

Feb 21, 2026

Feb 20, 2026

Boston Scientific Stock is Down 20% This Year. Here Is What Investors Need to Know Before March 28 - TIKR.com

Feb 20, 2026

BSX vs. ABT: Which MedTech Stock is the Better Investment Now? - Finviz

Feb 20, 2026

Feb 19, 2026